SCHEMBL19783319

SCHEMBL19783319

COc1cc(Cl)c2occc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.41
CYP3A4 P08684 3/20 0.41
CYP2A6 P11509 3/20 0.41
MAOA P21397 2/20 0.41
CYP2D6 P10635 2/20 0.41
CYP2C19 P33261 2/20 0.41
CYP2A13 Q16696 2/20 0.41
TSHR P16473 1/20 0.41
ACHE P22303 1/20 0.41
PDE4A P27815 1/20 0.41
MAPK1 P28482 1/20 0.41
SLC6A3 Q01959 1/20 0.41
MAOB P27338 1/20 0.38
NPC1 O15118 4/20 0.38
RAB9A P51151 4/20 0.38
MAPT P10636 3/20 0.38
KDM4E B2RXH2 2/20 0.38
ABL1 P00519 1/20 0.37
ABCB1 P08183 1/20 0.37
BCR P11274 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28941128 0.81 MAOA (0.33) CYP1A2CYP3A4CYP2A6MAOACYP2D6
SCHEMBL119906 0.79 CYP3A4 (0.47) CYP1A2CYP3A4CYP2A6MAOACYP2D6
SCHEMBL4984623 0.79 MAOA (0.42) CYP1A2CYP3A4CYP2A6MAOACYP2D6
SCHEMBL28792255 0.79 CYP3A4 (0.47) CYP1A2CYP3A4CYP2A6MAOACYP2D6
SCHEMBL10044955 0.79 CYP3A4 (0.42) CYP1A2CYP3A4CYP2A6MAOACYP2D6
SCHEMBL4295622 0.78 MAOA (0.48) CYP1A2CYP3A4CYP2A6MAOACYP2D6
SCHEMBL19782489 0.77 CA12 (0.40) CYP1A2CYP3A4CYP2A6MAOACYP2D6
SCHEMBL15180071 0.75 CA1 (0.47) CYP1A2CYP3A4CYP2A6MAOACYP2D6
SCHEMBL9098304 0.75 KCNA3 (0.41) CYP1A2CYP3A4CYP2A6MAOACYP2D6
SCHEMBL15298769 0.75 NPC1 (0.35) CYP1A2CYP3A4CYP2A6MAOACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-06-03 US disclosed
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BISTOL MYERS SQUIBB COMPANY (US) 2019-09-26 US disclosed
WO-2018013774-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, PF4 CYP1A2 200/4885CYP3A4 15/4885CYP2A6 214/4885
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, F12 CYP1A2 176/4885CYP3A4 18/4885CYP2A6 337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.